查詢結果分析
來源資料
頁籤選單縮合
| 題 名 | 藥物與免疫反應篩選之腫瘤微環境晶片開發=Tumor Microenvironments on a Chip for Drug and Immune-response Screening |
|---|---|
| 作 者 | 胡尚秀; 江銘仁; 邱凱雯; | 書刊名 | 科儀新知 |
| 卷 期 | 239 2024.06[民113.06] |
| 頁 次 | 頁33-41 |
| 專 輯 | 「器官晶片技術與應用」專題 |
| 分類號 | 448.65 |
| 關鍵詞 | 腫瘤微環境晶片; 癌症; 免疫治療; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 根據美國國家癌症研究所 (NCI) 的新統計研究顯示,未來 30 年美國老年人口罹患癌症 的數量將大幅增加。預估到 2040 年,美國癌症患者數量將增加 1100 萬,從目前的 61% 上 升至 73%,形成未來 30 年的「癌症銀海嘯」。臺灣同樣正面臨人口老齡化的挑戰,預料罹 癌人數將急速上升。根據衛生福利部統計,臺灣罹癌死亡率接近 30%,是國人十大死因之 首。儘管許多研究人員致力於開發有效的藥物傳遞系統以提高治癒率並降低化療副作用,但 成效仍然有限。主要原因在於腫瘤微環境的複雜性,導致體外藥物篩選時存在誤差,進而造 成許多臨床藥物測試失敗。為了實現精準模擬腫瘤微環境的目標,許多研究開發了模擬腫瘤 微環境晶片 (tumor microenvironment on a Chip, TMoC)。這些晶片可用於快速篩選和評估藥 物載體系統在腫瘤中的穿透性,並評估化學藥物和免疫治療的特性,以了解腫瘤微環境對藥 物和免疫治療的影響。TMoC 包含數百顆三維腫瘤細胞,包括血管、纖維母細胞、癌細胞、 癌幹細胞和巨噬細胞,並且可以及時評估藥物載體的穿透和治療效果,觀察各種細胞之間的 相互作用,並評估在 T 細胞作用下整體細胞的變化。 |
| 英文摘要 | According to a new statistical study published by the National Cancer Institute (NCI), the number of cancers in older adults in the United States will increase significantly in the next 30 years. It is estimated that the number of cancer patients in the United States will increase by 11 million in 2040 (from 61% to 73%), will be the cancer silver tsunami in the next 30 years. Taiwan’s aging society will also lead to a rapid increase in the number of cancer cases. According to statistics from the Ministry of Health and Welfare, Taiwan’s cancer mortality rate is close to 30%, ranking first among the top ten causes of death in the country. Although many researchers are committed to developing effective drug delivery systems to improve cure rates and reduce chemotherapy side effects, the results are still limited, mainly due to the complexity of the tumor microenvironment, which results in errors in in vitro drug screening and causes many clinical problems. In order to achieve the purpose of accurately simulating the tumor microenvironment in vitro, many research concepts are to develop tumor microenvironment on a chip (TMoC), which can be used to quickly screen and evaluate the penetration of drug carrier systems into tumors, and screen Characteristics of chemical drugs and immunotherapy, and understanding the impact of tumor microenvironment on drugs and immunotherapy. The TMoC contains more than hundreds of three-dimensional tumors (including blood vessels, fibroblasts, cancer cells, cancer stem cells, and macrophages). The penetration and therapeutic effect of the drug carrier can be evaluated in a timely manner, and the correlation between each cell can be observed and assess overall cellular changes under the influence of T cells. |
本系統中英文摘要資訊取自各篇刊載內容。